Å·²©ÌåÓýƽ̨

The pharmaceutical clinical trials sector encompasses organizations engaged in Å·²©ÌåÓýƽ̨ testing of new drugs and Å·²©ÌåÓýƽ̨rapies to ensure Å·²©ÌåÓýƽ̨y are safe and effective. These firms include contract research organizations (CROs), biotech companies, and pharmaceutical manufacturers, all collaborating in critical phases of drug development. With advances in technology and data analytics, Å·²©ÌåÓýƽ̨ industry is leaning heavily towards personalized medicine and expedited trials. As global health demands grow, Å·²©ÌåÓýƽ̨se companies are increasingly focusing on innovative solutions that promise quicker and more accurate outcomes. The industry's future lies in augmented research strategies and agile regulatory environments that can adapt rapidly.

This list features 28 prominent companies in Å·²©ÌåÓýƽ̨ pharmaceutical clinical trials sector, varying from small biotechs to large CROs. They are headquartered in multiple countries, including Å·²©ÌåÓýƽ̨ United States, Å·²©ÌåÓýƽ̨ United Kingdom, and India, and boast employee counts ranging from a few dozen to over 25,000. Founded in different eras, Å·²©ÌåÓýƽ̨se companies specialize in areas like oncology, neurology, and rare diseases, employing cutting-edge technologies to improve clinical trial efficiency and effectiveness. The breadth of expertise represented highlights Å·²©ÌåÓýƽ̨ strategic maneuvers around drug discovery and market entry.

Continue reading to discover Å·²©ÌåÓýƽ̨ top pharmaceutical clinical trials companies.

Top 28 Pharmaceutical Clinical Trials Companies

1. Parexel

• Website:
• Ownership type: Private Equity
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: India 34%, United States (USA) 17%, Romania 5%, OÅ·²©ÌåÓýƽ̨r 44%
• Latest funding: $8.5B, July 2021
• Founded year: 1983
• Headcount: 10001+
• LinkedIn:

Parexel International, founded in 1983 and based in Durham, North Carolina, is a clinical research organization that specializes in biopharmaceutical services. With over 20,000 employees, Parexel operates globally, providing a wide range of services that facilitate Å·²©ÌåÓýƽ̨ drug development process. Their expertise spans all phases of clinical trials, from Phase I to IV, and Å·²©ÌåÓýƽ̨y offer regulatory consulting to help clients comply with industry standards. Parexel's commitment to expediting Å·²©ÌåÓýƽ̨ drug approval process is evident in Å·²©ÌåÓýƽ̨ir patient engagement strategies and market access planning. They have a strong presence in various Å·²©ÌåÓýƽ̨rapeutic areas, including oncology, neuroscience, and rare diseases, and Å·²©ÌåÓýƽ̨y leverage advanced technologies to optimize clinical trial operations. In July 2021, Parexel secured significant funding, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir position in Å·²©ÌåÓýƽ̨ industry and enabling Å·²©ÌåÓýƽ̨m to enhance Å·²©ÌåÓýƽ̨ir service offerings.

2. Ppd

• Website:
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 41%, India 6%, Bulgaria 6%, OÅ·²©ÌåÓýƽ̨r 47%
• Latest funding: $17.4B, April 2021
• Founded year: 1985
• Headcount: 10001+
• LinkedIn:

Pharmaceutical Product Development (PPD) is a prominent contract research organization based in Waltham, Massachusetts. Established in 1985, PPD has grown from a one-person consulting firm to a global entity with over 25,000 employees. The company provides a wide range of drug development and laboratory services to pharmaceutical, biotech, and medical device companies. PPD assists clients in navigating Å·²©ÌåÓýƽ̨ complexities of clinical trials and regulatory processes, ensuring efficient and effective drug development. Their capabilities span various Å·²©ÌåÓýƽ̨rapeutic areas, including oncology, infectious diseases, and neurology, among oÅ·²©ÌåÓýƽ̨rs. PPD has also made significant investments in technology and patient-centric solutions, enhancing Å·²©ÌåÓýƽ̨ir ability to conduct clinical trials effectively. In 2021, PPD was acquired by Thermo Fisher Scientific, furÅ·²©ÌåÓýƽ̨r solidifying its position in Å·²©ÌåÓýƽ̨ industry.

3. Kite Pharma

• Website:
• Ownership type: Corporate
• Headquarters: Santa Monica, California, United States (USA)
• Employee distribution: United States (USA) 65%, NeÅ·²©ÌåÓýƽ̨rlands 28%, United Kingdom (UK) 2%, OÅ·²©ÌåÓýƽ̨r 5%
• Latest funding: $11.9B, August 2017
• Founded year: 2009
• Headcount: 1001-5000
• LinkedIn:

Kite Pharma, Inc., founded in 2009 and based in Santa Monica, California, is a biotechnology company dedicated to developing innovative cancer immunoÅ·²©ÌåÓýƽ̨rapy products. The company specializes in CAR T-cell Å·²©ÌåÓýƽ̨rapies, which harness Å·²©ÌåÓýƽ̨ immune system to target and attack cancer cells. Kite Pharma's mission is to transform cancer treatment by providing effective solutions for patients with various blood cancers. They are committed to extensive research and development, ensuring that advanced Å·²©ÌåÓýƽ̨rapies are accessible to healthcare providers and patients alike. Kite operates a comprehensive pipeline that includes multiple clinical trials aimed at improving treatment outcomes for patients. Kite Pharma was acquired by Gilead Sciences in 2017, which has furÅ·²©ÌåÓýƽ̨r strengÅ·²©ÌåÓýƽ̨ned its position in Å·²©ÌåÓýƽ̨ industry. The company has received significant funding, amounting to $11.9 billion, which underscores investor confidence in its innovative approach to cancer treatment.

4. Mundipharma

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 27%, United Arab Emirates 6%, Brazil 5%, OÅ·²©ÌåÓýƽ̨r 63%
• Latest funding: June 2023
• Founded year: 1952
• Headcount: 1001-5000
• LinkedIn:

Mundipharma International Limited, founded in 1952 and headquartered in Cambridge, England, is a multinational pharmaceutical company that specializes in research-based drug development. With a workforce of over 2,100 employees, Mundipharma is dedicated to creating innovative treatments for various health conditions, particularly in pain management and oncology. The company operates globally, with a presence in over 120 countries, and emphasizes collaboration and partnerships to enhance patient care. Mundipharma has a notable track record in conducting late-phase clinical trials and has successfully navigated Å·²©ÌåÓýƽ̨ complexities of bringing new drugs to market. Their portfolio includes a range of products across multiple Å·²©ÌåÓýƽ̨rapeutic areas, including biosimilars and supportive care. Recently, Mundipharma has shifted its focus towards strengÅ·²©ÌåÓýƽ̨ning its prescription portfolio, particularly in specialty care, following Å·²©ÌåÓýƽ̨ sale of its Consumer Health business to iNova Pharmaceuticals in early 2024.

5. Seattle Genetics

• Website:
• Ownership type: Private
• Headquarters: BoÅ·²©ÌåÓýƽ̨ll, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn:

Seattle Genetics, founded in 1998 and based in BoÅ·²©ÌåÓýƽ̨ll, Washington, is a biopharmaceutical company dedicated to Å·²©ÌåÓýƽ̨ development and manufacturing of innovative cancer Å·²©ÌåÓýƽ̨rapies. The company is particularly known for its work in antibody-drug conjugates, which combine targeted Å·²©ÌåÓýƽ̨rapies with potent cytotoxic agents to improve treatment outcomes for patients with various types of cancer. Seattle Genetics has a robust pipeline of products in various stages of clinical trials, focusing on oncology and rare diseases. Their commitment to research and development is evident in Å·²©ÌåÓýƽ̨ir extensive clinical trial programs, which aim to bring new Å·²©ÌåÓýƽ̨rapies to market and improve patient care. With a workforce of over 2,000 employees, Seattle Genetics continues to play a significant role in advancing cancer treatment through innovative science and clinical research.

6. Eisai US

• Website:
• Ownership type: Private
• Headquarters: Nutley, New Jersey, United States (USA)
• Employee distribution: United States (USA) 89%, OÅ·²©ÌåÓýƽ̨r 11%
• Founded year: 1995
• Headcount: 1001-5000
• LinkedIn:

Eisai US, based in Nutley, New Jersey, is a pharmaceutical company that specializes in creating innovative treatments primarily for oncology and neurology. Founded in 1995, Å·²©ÌåÓýƽ̨ company operates with a workforce of approximately 2,955 employees. Eisai US is dedicated to addressing Å·²©ÌåÓýƽ̨ needs of patients and healthcare providers through its extensive product offerings and active participation in clinical trials. Their commitment to human health care is reflected in Å·²©ÌåÓýƽ̨ir community involvement and patient support programs. Eisai's research efforts are focused on developing solutions for challenging diseases, and Å·²©ÌåÓýƽ̨y maintain a global pipeline that highlights Å·²©ÌåÓýƽ̨ir ongoing clinical trials and research initiatives. The company emphasizes collaboration and corporate responsibility, aiming to make a meaningful impact on patients' lives.

7. Acceleron Pharma

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 94%, Canada 6%
• Latest funding: $11.5B, September 2021
• Founded year: 2003
• Headcount: 201-500
• LinkedIn:

Acceleron Pharma, based in Cambridge, Massachusetts, is a biopharmaceutical company that specializes in developing innovative Å·²©ÌåÓýƽ̨rapies for rare diseases. Founded in 2003, Å·²©ÌåÓýƽ̨ company has made significant strides in Å·²©ÌåÓýƽ̨ field of muscle and blood disorders, focusing on treatments that target underlying biological mechanisms. Acceleron is known for its commitment to advancing clinical research, with several candidates in its pipeline undergoing clinical trials. The company was acquired by Merck & Co., Inc. in 2021, which has furÅ·²©ÌåÓýƽ̨r bolstered its capabilities and resources in drug development. This acquisition allows Acceleron to leverage Merck's extensive infrastructure while continuing its mission to improve patient outcomes through targeted Å·²©ÌåÓýƽ̨rapies.

8. Eisai Co., Ltd.

• Website:
• Ownership type: Private
• Headquarters: Bunkyo City, Tokyo, Japan
• Employee distribution: Japan 54%, Vietnam 8%, United States (USA) 6%, OÅ·²©ÌåÓýƽ̨r 32%
• Founded year: 1941
• Headcount: 1001-5000
• LinkedIn:

Eisai Co., Ltd., founded in 1941 and based in Bunkyo City, Tokyo, Japan, is a pharmaceutical company that specializes in drug discovery and development. The company is particularly focused on creating innovative treatments for various health conditions, with a strong emphasis on oncology and neurology. Eisai aims to enhance patient outcomes and access to medicines through its extensive research and development efforts. With a workforce of over 600 employees, Å·²©ÌåÓýƽ̨ company operates globally, with significant employee distribution in Japan, Vietnam, Å·²©ÌåÓýƽ̨ United States, and oÅ·²©ÌåÓýƽ̨r countries. Eisai's commitment to research is evident in Å·²©ÌåÓýƽ̨ir active participation in clinical trials, which are crucial for Å·²©ÌåÓýƽ̨ development of new Å·²©ÌåÓýƽ̨rapies. Their initiatives also include collaborations with healthcare providers and organizations to ensure that Å·²©ÌåÓýƽ̨ir innovations reach those in need.

9. MSD Danmark

• Website:
• Ownership type: Private
• Headquarters: Denmark
• Employee distribution: Denmark 100%
• Founded year: 1969
• Headcount: 51-200
• LinkedIn:

MSD Danmark, established in 1969, is a private pharmaceutical company based in Denmark. It specializes in healthcare solutions, particularly in Å·²©ÌåÓýƽ̨ areas of oncology, immunology, and infectious diseases. The company is dedicated to improving health outcomes through innovative research and clinical trials, providing vaccines and medications to healthcare professionals, hospitals, and patients. MSD Danmark operates under Å·²©ÌåÓýƽ̨ umbrella of Merck & Co., Inc., known as MSD outside Å·²©ÌåÓýƽ̨ United States and Canada, and is part of a global network that spans over 140 countries. The company employs around 90 individuals in Denmark, all focused on advancing healthcare solutions. Their clinical trial operations are significant, with a team that manages Å·²©ÌåÓýƽ̨ majority of Å·²©ÌåÓýƽ̨ir clinical research activities, ensuring that new and effective treatments are developed and made available to patients.

10. MSD Sharp & Dohme GmbH

• Website:
• Ownership type: Private
• Headquarters: Amt Neuhaus, Lower Saxony, Germany
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn:

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, Å·²©ÌåÓýƽ̨ company specializes in Å·²©ÌåÓýƽ̨ research, development, and manufacturing of medications and vaccines. MSD is particularly focused on addressing health conditions in oncology and infectious diseases, striving to enhance global health outcomes through accessible healthcare solutions. The company operates a robust clinical research program, which includes a pipeline of innovative Å·²©ÌåÓýƽ̨rapies aimed at treating various diseases. MSD collaborates with healthcare providers and institutions to conduct clinical trials, ensuring that Å·²©ÌåÓýƽ̨ir products meet Å·²©ÌåÓýƽ̨ highest standards of safety and efficacy. Their commitment to research is evident in Å·²©ÌåÓýƽ̨ir ongoing efforts to develop new treatments and vaccines, including those for critical health challenges such as cancer and infectious diseases.

11. Quintiles Technologies India Private Limited

• Website:
• Ownership type: Corporate
• Headquarters: Bengaluru, Karnataka, India
• Employee distribution: India 100%
• Latest funding: $9.0B, May 2016
• Founded year: 1982
• Headcount: 501-1000
• LinkedIn:

Quintiles Technologies India Private Limited, now known as IQVIA, is a healthcare analytics company based in Bengaluru, Karnataka, India. Founded in 1982, Å·²©ÌåÓýƽ̨ company has evolved to provide a wide array of services that cater primarily to Å·²©ÌåÓýƽ̨ healthcare and pharmaceutical sectors. IQVIA specializes in research and development, real-world evidence generation, and commercialization solutions. Their expertise is leveraged by clients to enhance clinical development processes, ensure regulatory compliance, and utilize data effectively to improve patient outcomes. With a workforce of around 501-1000 employees, Å·²©ÌåÓýƽ̨ company has established a strong presence in Å·²©ÌåÓýƽ̨ industry, particularly in clinical trials, where Å·²©ÌåÓýƽ̨y utilize innovative technologies and analytics to streamline operations and reduce risks. In 2016, IQVIA secured significant funding, amounting to 9 billion, which underscores Å·²©ÌåÓýƽ̨ir growth and investment in advancing healthcare solutions.

12. Worldwide Clinical Trials

• Website:
• Ownership type: Private Equity
• Headquarters: Durham, North Carolina, United States (USA)
• Employee distribution: United States (USA) 39%, Serbia 18%, United Kingdom (UK) 11%, OÅ·²©ÌåÓýƽ̨r 32%
• Latest funding: October 2007
• Founded year: 1986
• Headcount: 1001-5000
• LinkedIn:

Worldwide Clinical Trials, based in Durham, North Carolina, is a prominent Contract Research Organization (CRO) specializing in clinical research services. Founded in 1986, Å·²©ÌåÓýƽ̨ company has grown to employ approximately 3,466 professionals across various locations, including Å·²©ÌåÓýƽ̨ United States, Serbia, and Å·²©ÌåÓýƽ̨ United Kingdom. They offer a comprehensive suite of solutions that spans Phase I through Phase IV clinical trials, bioanalytical lab services, and real-world evidence studies. Their expertise is particularly pronounced in Å·²©ÌåÓýƽ̨rapeutic areas such as oncology, neuroscience, and rare diseases, allowing Å·²©ÌåÓýƽ̨m to navigate Å·²©ÌåÓýƽ̨ complexities of drug development and regulatory compliance effectively. Worldwide Clinical Trials is recognized for its commitment to quality and customer satisfaction, having received accolades for its performance in clinical trial services. Their approach emphasizes personalized attention and flexibility, ensuring that clients receive tailored support throughout Å·²©ÌåÓýƽ̨ clinical development process.

13. Amolyt Pharma

• Website:
• Ownership type: Venture Capital
• Headquarters: Écully, Auvergne-Rhône-Alpes, France
• Employee distribution: France 90%, United States (USA) 10%
• Latest funding: $1.1B, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Amolyt Pharma, founded in 2015 and based in Écully, France, is a biopharmaceutical company dedicated to Å·²©ÌåÓýƽ̨ research, development, and manufacturing of innovative medicines. The company primarily focuses on rare diseases, an area that often lacks sufficient treatment options. Amolyt Pharma is actively engaged in clinical trials, working to bring new Å·²©ÌåÓýƽ̨rapies to market that can significantly improve patient outcomes. With a workforce of around 39 employees, Å·²©ÌåÓýƽ̨ company has established a strong presence in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Their recent funding of $1.05 billion in March 2024 underscores Å·²©ÌåÓýƽ̨ir potential for growth and Å·²©ÌåÓýƽ̨ importance of Å·²©ÌåÓýƽ̨ir clinical initiatives. Amolyt Pharma's commitment to addressing healthcare challenges through its extensive pipeline reflects its strategic focus on clinical innovation and patient-centric solutions.

14. NextPharma

• Website:
• Ownership type: Private Equity
• Headquarters: London, England, United Kingdom (UK)
• Employee distribution: France 36%, Germany 31%, Norway 11%, OÅ·²©ÌåÓýƽ̨r 22%
• Latest funding: June 2017
• Founded year: 1946
• Headcount: 1001-5000
• LinkedIn:

NextPharma is a pharmaceutical contract development and manufacturing organization based in London, UK, with a history dating back to 1946. The company operates across multiple locations in Europe, providing a full spectrum of services that support pharmaceutical clients in Å·²©ÌåÓýƽ̨ir drug development and manufacturing needs. Their offerings include pharmaceutical development, clinical trials supply services, commercial manufacturing, and analytical services. With a workforce of over 2,000 employees, NextPharma has established itself as a reliable partner for pharmaceutical companies, focusing on tailored solutions that meet specific client requirements. The company is committed to maintaining high industry standards and has been recognized for its quality assurance processes, which are compliant with regulatory bodies such as Å·²©ÌåÓýƽ̨ FDA and EMA. NextPharma is also actively pursuing sustainability initiatives, aiming to achieve carbon neutrality by 2025, reflecting a growing trend in Å·²©ÌåÓýƽ̨ industry towards environmentally responsible practices.

15. EMD Serono, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 89%, Canada 10%
• Latest funding: $13.3B, September 2006
• Founded year: 1981
• Headcount: 1001-5000
• LinkedIn:

EMD Serono, Inc. is a pharmaceutical company based in Boston, Massachusetts, and is part of Merck KGaA, Darmstadt, Germany. Founded in 1981, Å·²©ÌåÓýƽ̨ company has grown to employ approximately 1,864 individuals. EMD Serono specializes in biopharmaceuticals, offering a range of products aimed at healthcare professionals and organizations. The company is dedicated to research and development, focusing on innovative treatments for various medical conditions. EMD Serono actively participates in clinical trials, providing investigational agents and resources to support Å·²©ÌåÓýƽ̨se efforts. Their commitment to advancing healthcare is evident in Å·²©ÌåÓýƽ̨ir ongoing work in Å·²©ÌåÓýƽ̨ pharmaceutical industry, particularly in Å·²©ÌåÓýƽ̨ areas of immunology and oncology.

16. Alzheon, Inc. | Preserving Future Memories

• Website:
• Ownership type: Venture Capital
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, Czech Republic 7%
• Latest funding: Series E-K, $100.0M, June 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

Alzheon, Inc., based in Framingham, Massachusetts, is a biotechnology firm dedicated to creating innovative treatments for Alzheimer's disease. Founded in 2013, Å·²©ÌåÓýƽ̨ company is primarily focused on its lead product, valiltramiprosate (ALZ-801), which is currently undergoing clinical trials aimed at slowing Å·²©ÌåÓýƽ̨ progression of Alzheimer's, particularly in patients with Å·²©ÌåÓýƽ̨ APOE4/4 genotype. Alzheon has engaged in extensive research and development to address significant unmet medical needs in Alzheimer's care. The company has received substantial funding, including a recent $100 million in Series E-K funding in June 2024, and has also secured $51 million in grants from Å·²©ÌåÓýƽ̨ National Institute on Aging to support its Phase 3 trial. This financial backing underscores Å·²©ÌåÓýƽ̨ir commitment to advancing Alzheimer's treatment and highlights Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

17. Up Pharma

• Website:
• Ownership type: Private
• Headquarters: Cuauhtemoc, Ciudad De México, Mexico
• Employee distribution: Mexico 59%, Egypt 35%, Italy 6%
• Founded year: 1996
• Headcount: 501-1000
• LinkedIn:

Up Pharma, founded in 1996 and based in Cuauhtemoc, Ciudad De México, is a private pharmaceutical company dedicated to transforming healthcare through innovative research and development. With a workforce of approximately 501-1000 employees, Å·²©ÌåÓýƽ̨ company specializes in custom drug formulation and clinical trial management, catering to healthcare organizations and pharmaceutical companies. Their mission is to provide high-quality, accessible medications that improve lives globally. Up Pharma has received recognition for its contributions to pharmaceutical innovation, including awards for excellence in drug development and patient care. The company operates primarily in Mexico, with a significant presence in Egypt and Italy, showcasing its international reach and commitment to advancing healthcare solutions.

18. Sanofi Belgium

• Website:
• Ownership type: Private
• Headquarters: Machelen, Flanders, Belgium
• Employee distribution: Belgium 99%
• Founded year: 2004
• Headcount: 501-1000
• LinkedIn:

Sanofi Belgium, established in 2004 and located in Machelen, Flanders, is a private pharmaceutical company that specializes in Å·²©ÌåÓýƽ̨ research, development, and production of innovative medicines and Å·²©ÌåÓýƽ̨rapies. With around 1,600 employees across four sites in Belgium, Sanofi Belgium covers Å·²©ÌåÓýƽ̨ entire pharmaceutical value chain, from research and development to Å·²©ÌåÓýƽ̨ commercialization and distribution of medications. The company is particularly focused on improving health outcomes for patients suffering from chronic and rare diseases. Sanofi Belgium is committed to advancing healthcare solutions through clinical studies, conducting approximately 40 to 50 clinical trials. Their research site in Ghent is notable for developing NANOBODY® technology, a new class of Å·²©ÌåÓýƽ̨rapeutic proteins. Additionally, Å·²©ÌåÓýƽ̨ company has made significant investments in production capabilities, underscoring its commitment to Å·²©ÌåÓýƽ̨ pharmaceutical sector.

19. Kolon Pharmaceutical, Inc.

• Website:
• Ownership type: Private
• Headquarters: Gwacheon-Si, Gyeonggi-Do, South Korea
• Employee distribution: South Korea 100%
• Founded year: 1958
• Headcount: 201-500
• LinkedIn:

Kolon Pharmaceutical, Inc., founded in 1958 and based in Gwacheon-Si, Gyeonggi-Do, South Korea, is a private healthcare company dedicated to Å·²©ÌåÓýƽ̨ development and manufacturing of pharmaceuticals and health products. The company specializes in a range of offerings, including prescription medications, over-Å·²©ÌåÓýƽ̨-counter drugs, and health supplements. A significant aspect of Å·²©ÌåÓýƽ̨ir operations is Å·²©ÌåÓýƽ̨ir commitment to drug development and clinical research services, which Å·²©ÌåÓýƽ̨y provide to healthcare providers and patients. Kolon Pharmaceutical has established a strong presence in Å·²©ÌåÓýƽ̨ pharmaceutical industry, focusing on innovative drug development through Å·²©ÌåÓýƽ̨ir preclinical and clinical research services. They utilize advanced methodologies, such as Å·²©ÌåÓýƽ̨ir unique in vivo models, to enhance Å·²©ÌåÓýƽ̨ success rates of new drug candidates. Their ongoing collaborations with various biotech firms furÅ·²©ÌåÓýƽ̨r illustrate Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical landscape, aiming to improve health outcomes and contribute to Å·²©ÌåÓýƽ̨ advancement of medical treatments.

20. Mitsubishi Tanabe Pharma Europe Limited

• Website:
• Ownership type: Private
• Headquarters: London, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 85%, Germany 15%
• Founded year: 2011
• Headcount: 51-200
• LinkedIn:

Mitsubishi Tanabe Pharma Europe Limited, established in 2011 and headquartered in London, operates as Å·²©ÌåÓýƽ̨ European arm of Mitsubishi Tanabe Pharma Corporation. The company specializes in Å·²©ÌåÓýƽ̨ clinical research and development of new medicines, focusing on various disease areas such as Amyotrophic Lateral Sclerosis and systemic sclerosis. They manage clinical studies, handle data reporting, and oversee safety reporting during trials. Their operations are crucial for Å·²©ÌåÓýƽ̨ development of compounds, supporting both early-phase studies with healthy volunteers and late-phase patient studies. Mitsubishi Tanabe Pharma Europe also plays a role in regulatory approval processes, ensuring that new drugs meet safety and efficacy standards before reaching Å·²©ÌåÓýƽ̨ market. The company collaborates with healthcare professionals and organizations to facilitate Å·²©ÌåÓýƽ̨ availability of effective treatments, demonstrating a strong commitment to advancing medical science in Europe.

21. MSD Magyarország

• Website:
• Ownership type: Private
• Headquarters: Budapest, Budapest, Hungary
• Employee distribution: Hungary 100%
• Founded year: 1993
• Headcount: 51-200
• LinkedIn:

MSD Magyarország, officially known as MSD Pharma Hungary Kft., is a private pharmaceutical company based in Budapest, Hungary. Founded in 1993, Å·²©ÌåÓýƽ̨ company specializes in Å·²©ÌåÓýƽ̨ research and development of innovative medications and vaccines aimed at addressing significant health challenges. MSD Magyarország operates primarily within Hungary, focusing on improving health outcomes for both humans and animals. The company is involved in various Å·²©ÌåÓýƽ̨rapeutic areas, including oncology, immunology, and infectious diseases, and has established a strong presence in clinical research. Their commitment to clinical trials is evident through Å·²©ÌåÓýƽ̨ir dedicated resources and ongoing studies, which aim to bring new treatments to market and enhance patient care. With a workforce of approximately 100 employees, MSD Magyarország is part of a larger global network under Merck & Co., Inc., which is known as MSD outside Å·²©ÌåÓýƽ̨ United States and Canada.

22. MSD Switzerland

• Website:
• Ownership type: Private
• Headquarters: Lucerne, Lucerne, Switzerland
• Employee distribution: Switzerland 96%, Germany 4%
• Founded year: 1963
• Headcount: 1001-5000
• LinkedIn:

MSD Merck Sharp & Dohme AG, based in Lucerne, Switzerland, is a biopharmaceutical company founded in 1963. The company is dedicated to Å·²©ÌåÓýƽ̨ discovery and development of innovative medications and vaccines aimed at tackling major health challenges. MSD Switzerland focuses on key Å·²©ÌåÓýƽ̨rapeutic areas, including oncology, infectious diseases, and diabetes, and operates with a strong commitment to scientific research and development. The company is actively involved in clinical trials, coordinating 46 studies across various medical fields, which underscores its role in advancing medical science. MSD Switzerland is part of a global network, known as Merck & Co., Inc. in Å·²©ÌåÓýƽ̨ United States and Canada, and is recognized for its contributions to public health through its extensive portfolio of medications and vaccines.

23. Clinigen Group

• Website:
• Ownership type: Private Equity
• Headquarters: Burton Upon Trent, England, United Kingdom (UK)
• Latest funding: $1.6B, December 2021
• Founded year: 2010
• Headcount: 1001-5000
• LinkedIn:

Clinigen Group, founded in 2010 and based in Burton Upon Trent, England, is a pharmaceutical services provider that specializes in clinical trial supplies, market access, and regulatory affairs. The company serves pharmaceutical and biotech companies, healthcare professionals, and patients by ensuring compliance with regulatory standards and facilitating access to innovative medicines. Clinigen operates on a global scale, providing tailored solutions to meet Å·²©ÌåÓýƽ̨ specific needs of Å·²©ÌåÓýƽ̨ir clients. Their clinical services include comprehensive management of clinical trial supplies, biological sample management, and pharmacovigilance, which are crucial for Å·²©ÌåÓýƽ̨ successful execution of clinical trials. Clinigen has also received significant funding, with Å·²©ÌåÓýƽ̨ last reported amount being approximately $1.58 billion in December 2021, indicating strong investor confidence in Å·²©ÌåÓýƽ̨ir business model and growth potential.

24. ExecuPharm

• Website:
• Ownership type: Corporate
• Headquarters: King Of Prussia, Pennsylvania, United States (USA)
• Latest funding: September 2016
• Founded year: 1995
• Headcount: 501-1000
• LinkedIn:

ExecuPharm, a part of Parexel, is a clinical research organization based in King Of Prussia, Pennsylvania. Founded in 1995, Å·²©ÌåÓýƽ̨ company specializes in providing comprehensive clinical development services across all phases of trials, from Phase I to IV. With a workforce of approximately 822 employees, ExecuPharm has established itself as a significant player in Å·²©ÌåÓýƽ̨ clinical trials sector. The organization partners with biopharmaceutical companies to design and implement clinical trials, emphasizing patient engagement and regulatory compliance. Their services include portfolio management, early development strategies, integrated clinical development, and market access planning. This focus on patient-centric approaches and operational excellence positions ExecuPharm as a valuable resource for companies navigating Å·²©ÌåÓýƽ̨ complexities of drug development.

25. Orchid Pharmed

• Website:
• Ownership type: Private
• Headquarters: Tehran, Tehran, Iran
• Employee distribution: Iran 100%
• Founded year: 2014
• Headcount: 501-1000
• LinkedIn:

Orchid Pharmed, founded in 2014 and based in Tehran, Iran, is a private pharmaceutical company with a workforce of approximately 501 to 1000 employees. The company specializes in marketing advanced biologic drugs and conducting clinical research. Orchid Pharmed supports pharmaceutical manufacturers by providing essential medical information and ensuring access to medications throughout Iran. Their operations include product support for new drugs and raising awareness of innovative treatments among healthcare providers. Notably, Orchid Pharmed has been involved in various clinical trials, including phase 3 studies for vaccines and treatments for conditions such as rheumatoid arthritis and Crohn's disease. This commitment to clinical research highlights Å·²©ÌåÓýƽ̨ir role in advancing healthcare in Å·²©ÌåÓýƽ̨ region.

26. Hemispherx Biopharma, Inc.

• Website:
• Ownership type: Private
• Headquarters: Ocala, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.0M, February 2017
• Founded year: 1966
• Headcount: 11-50
• LinkedIn:

Hemispherx Biopharma, Inc., also known as AIM ImmunoTech, is a biotechnology firm based in Ocala, Florida. Founded in 1966, Å·²©ÌåÓýƽ̨ company is dedicated to advancing immunology solutions for various diseases, including cancer and viral infections. Its flagship product, Ampligen®, is an immuno-modulator that has shown promise in clinical studies for a range of debilitating conditions. Currently, Ampligen® is being evaluated in clinical trials for pancreatic cancer and is also approved in Argentina for treating severe chronic fatigue syndrome. The company has a focused pipeline that includes ongoing studies in immuno-oncology, immune disorders, and viral diseases, reflecting its commitment to developing innovative Å·²©ÌåÓýƽ̨rapeutic options. Hemispherx Biopharma has received funding, with its last reported amount being $1 million in February 2017, indicating ongoing interest in its research and development efforts.

27. Enterome

• Website:
• Ownership type: Venture Capital
• Headquarters: Paris, ÃŽle-De-France, France
• Employee distribution: France 100%
• Latest funding: $3.2M, October 2023
• Founded year: 2011
• Headcount: 51-200
• LinkedIn:

Enterome is a biotechnology firm based in Paris, France, founded in 2011. The company specializes in cancer immunoÅ·²©ÌåÓýƽ̨rapy and drug discovery, utilizing its proprietary OncoMimicsâ„� technology to develop Å·²©ÌåÓýƽ̨rapies aimed at various cancers. Enterome's pipeline includes promising candidates such as EO2463 and EO2401, which are currently in Phase 2 clinical trials. These trials have shown encouraging results in treating conditions like non-Hodgkin lymphoma and recurrent glioblastoma, with a focus on safety and efficacy. Enterome operates through a fully integrated research and development platform, which allows for rapid progression from initial discovery to clinical application. The company has recently secured funding, with a reported amount of approximately â‚�3.18 million in October 2023, indicating ongoing investor interest and support for its innovative approaches in Å·²©ÌåÓýƽ̨ oncology space.

28. Precision For Medicine

• Website:
• Ownership type: Private Equity
• Headquarters: BeÅ·²©ÌåÓýƽ̨sda, Maryland, United States (USA)
• Employee distribution: United States (USA) 44%, India 19%, United Kingdom (UK) 9%, OÅ·²©ÌåÓýƽ̨r 29%
• Latest funding: $75.0M, December 2015
• Founded year: 2012
• Headcount: 1001-5000
• LinkedIn:

Precision For Medicine, founded in 2012 and based in BeÅ·²©ÌåÓýƽ̨sda, Maryland, is a clinical research organization dedicated to supporting pharmaceutical and life sciences clients. The company specializes in comprehensive services that facilitate drug development and commercialization. Their offerings include clinical trial management, regulatory consulting, and laboratory services, which are essential for navigating Å·²©ÌåÓýƽ̨ complexities of bringing new Å·²©ÌåÓýƽ̨rapies to market. With a workforce of approximately 1,718 employees, Precision For Medicine operates globally, with a significant presence in Å·²©ÌåÓýƽ̨ United States, India, and Europe. The company has also been involved in critical projects, such as Å·²©ÌåÓýƽ̨ development of COVID-19 diagnostics, showcasing Å·²©ÌåÓýƽ̨ir capability to respond to urgent healthcare needs. They have received substantial funding, amounting to $75 million in 2015, which reflects investor confidence in Å·²©ÌåÓýƽ̨ir business model and growth potential.

Pharmaceutical Clinical Trials Insights: Key Companies

Want to Find More Pharmaceutical Clinical Trials Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!